2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.33: Amivantamab plus Chemotherapy as First-line Treatment Among Hispanic/Latinos harboring EGFR Exon 20 Insertions Mutated NSCLC: PAPILLON Subgroup Analysis

PP01.33: Amivantamab plus Chemotherapy as First-line Treatment Among Hispanic/Latinos harboring EGFR Exon 20 Insertions Mutated NSCLC: PAPILLON Subgroup Analysis

Back to course

Pdf Summary

The Phase 3 PAPILLON trial evaluated the combination of amivantamab, an EGFR-MET bispecific antibody, with chemotherapy versus chemotherapy alone for patients with non-small cell lung cancer (NSCLC) featuring EGFR Exon 20 insertions (Ex20ins). The trial, presented at the Latin America Conference on Lung Cancer, highlighted significant improvements for patients receiving amivantamab-chemotherapy in progression-free survival (PFS) and objective response rate (ORR).<br /><br />In the Hispanic/Latinos subgroup, which included 22 participants (13 receiving amivantamab-chemotherapy and 9 chemotherapy), results mirrored the overall population's trends. The amivantamab-chemotherapy group showed a significantly higher ORR (92.3% vs. 33.3% for chemotherapy) and longer duration of response (median 8.71 months vs. 2.63 months). PFS for the amivantamab-chemotherapy group in Hispanic/Latinos was markedly improved (10.09 months vs. 6.7 months for chemotherapy), reducing the risk of progression or death by 88%.<br /><br />These findings led to the FDA approving the combination therapy as the first-line standard of care for advanced NSCLC with EGFR Ex20ins mutations. The safety profile in the Hispanic/Latinos subgroup was consistent with the overall trial results, with manageable adverse effects, including rash and infusion-related reactions, mostly being grade 1 or 2.<br /><br />Overall, the study emphasizes amivantamab-chemotherapy's efficacy and safety across diverse populations, reinforcing its role as a new standard treatment for this specific NSCLC variant.

Asset Subtitle

Oscar Arrieta

Keywords

PAPILLON trial

amivantamab

EGFR-MET bispecific antibody

chemotherapy

non-small cell lung cancer

EGFR Exon 20 insertions

progression-free survival

objective response rate

Hispanic/Latinos subgroup

FDA approval